Biotech stock Neurocrine surges more than 22% after FDA approves first drug for movement disorder

Shares of Neurocrine Biosciences leaped more than 22 percent Wednesday after the biotech firm announced federal approval of its drug for a movement disorder. Neurocrine announced late Tuesday that the Food and Drug Administration has approved Ingrezza, the only...

You can now go to college for free in two of the most expensive places in the US

The program covers the cost of a four-year college education for students from 940,000 middle-class families and will be phased in over three years. By 2019, students from families that make up to $125,000 would be eligible to attend all State University of New York...